drugset / Trial / NCT04326764
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Phase 3
Terminated
52 enrolled
Goethe University
Polish Adult Leukemia Group · collabSchweizerische Arbeitsgemeinschaft für klinische Krebsforschung · collabStichting Hemato-Oncologie voor Volwassenen Nederland · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Aim of this prospective randomized trial is to compare maintenance treatment with panobinostat interspersed with donor lymphocyte infusions (DLI) versus the standard approach of pre-emptive DLI alone in patients with poor-risk AML/MDS having favorably received an allogeneic HSCT followed by engraftment, donor chimerism and hematopoietic reconstitution.
Timeline
- Start
- 2018-07-24
- Primary completion
- 2023-02-13
- Completion
- 2023-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 20 mg | Oral |